Videos

Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.

Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.

Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.

Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.

Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.

Kerry Rogers, MD, discusses her study on real world-data regarding the cost of treatment for tumor lysis syndrome in patients with CLL and SLL, presented at the 2021 ASH Annual Meeting and Exposition.

Frederick Schnell, MD, and Sibel Blau, MD, discuss the rapid evolution of cancer care delivery and value based care in the Quality Cancer Care Alliance Network.

Sarah Temkin, MD, discusses a national survey of ovarian cancer care programs in the United States, identifying the needs of patients and informing quality improvement initiatives for these programs.